SiBone (SIBN)
(Delayed Data from NSDQ)
$13.63 USD
+0.14 (1.04%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $13.64 +0.01 (0.07%) 4:34 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.63 USD
+0.14 (1.04%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $13.64 +0.01 (0.07%) 4:34 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Zacks News
Chemed (CHE) Faces Macroeconomic Woes, Tough Competition
by Zacks Equity Research
Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth.
Vicarious Surgical (RBOT) to Broaden User Network With New Deal
by Zacks Equity Research
Vicarious Surgical's (RBOT) partnership with Intermountain Health is likely to help the company gain access to Intermountain Health's extensive network.
CVS Health's (CVS) New COVID-19 Vaccine Available at Its Stores
by Zacks Equity Research
CVS Health's (CVS) updated mRNA COVID-19 vaccine is now available at all its pharmacy locations.
Walgreens (WBA) Expands Primary Care Research With New Pact
by Zacks Equity Research
Walgreens (WBA) will reach more communities quickly and provide comprehensive, cost-effective care with the new collaboration.
SmileDirectClub (SDC) New Alliances Aid, Macro Woes Hurt
by Zacks Equity Research
SmileDirectClub (SDC) is focused on developing transformative innovations to serve the growing needs of the current customer base and expanded segments of higher-income demographics.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet.
Syneos Health (SYNH) Declares Strategic Partnership With Oracle
by Zacks Equity Research
Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.
Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems
by Zacks Equity Research
Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.
Insulet (PODD) Expands Omnipod 5 Even As Macro Woes Linger
by Zacks Equity Research
Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.
QIAGEN's (QGEN) New API Streamlines Access to BKB Data
by Zacks Equity Research
QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.
NanoString (NSTG) Grows in Translational Research With CRO Deals
by Zacks Equity Research
According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.
Thermo Fisher (TMO) to Advance Clinical Research With New Pact
by Zacks Equity Research
Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies.
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
by Zacks Equity Research
Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.
Align Technologies (ALGN) Brings New Upgrades for Oral Health
by Zacks Equity Research
Align Technologies (ALGN) introduces a series of software innovations to accelerate the digital practice transformation.
Globus Medical (GMED) Launches NuVasive's NSO in Global Market
by Zacks Equity Research
Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.
National Vision (EYE) Gains From Store Opening Amid Macro Woes
by Zacks Equity Research
In terms of store expansion, National Vision (EYE) continues to see a sizable new opportunity with growth for the coming years.
Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
by Zacks Equity Research
Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
by Zacks Equity Research
Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.
Align Technologies (ALGN) Set to Acquire Cubicure GmbH
by Zacks Equity Research
Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.